PPMW responds to 5th Circuit Court ruling on Mifepristone access
WASHINGTON,
Mifepristone has been used by 7.5 million women since it received Food and Drug Administration (FDA) approval 25 years ago. Overwhelming medical and scientific evidence supports the safety and efficacy of Mifepristone. Medication abortion accounts for 63% of all
On
PPMW President and CEO Dr.
"While we are relieved, for the sake of our patients, that the Supreme Court issued a hold on the 5th Circuit ruling, we are – also for the sake of our patients – outraged that access to safe and effective at-home medication abortion was threatened in the first place and that it remains in jeopardy. Ultimately, this is the result of politically motivated attacks against abortion in all its forms. The goal of anti-abortion extremists is to make it harder for everyone everywhere to get an abortion – including in DC,
For now, due to the provisional hold issued by the Supreme Court, PPMW can continue dispensing Mifepristone by mail and via certified pharmacies until at least
Planned Parenthood of Metropolitan Washington, DC (PPMW) provides high-quality and affordable reproductive health care, promotes education programs that empower all individuals to make informed reproductive choices, and protects the right to make those choices. PPMW is the oldest and largest provider of family planning services in Metropolitan Washington, serving
View original content to download multimedia:https://www.prnewswire.com/news-releases/ppmw-responds-to-5th-circuit-court-ruling-on-mifepristone-access-302761940.html
SOURCE Planned Parenthood of Metropolitan
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Back to School with Zum: The Most Important Commute in America Begins Again
- Kimbell Royalty Partners Closes $221.2 Million Drop Down Acquisition
- FLUENT Reports Second Quarter 2026 Results
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share